Efferocytosis‐Driven Reduction of Neuroinflammation and Amyloid Beta Burden via Novel GAS6 Fusion Protein, GAIA: A Promising Therapeutic Approach in Alzheimer's Disease

Abstract

Background: Amyloid‐beta (Aβ) accumulation is a hallmark of Alzheimer's disease (AD), and reducing Aβ burden is a key therapeutic strategy. Recent FDA‐approved anti‐Aβ antibodies, such as Lecanemab and Donanemab, have demonstrated significant reductions in Aβ burden and deceleration of cognitive decline.

The paper